In NPC's comments on the International Pricing Index Model for Medicare Part B Drugs, we identify critical methodological limitations associated with the IPI Model, which ultimately undermine the agency’s goal of prioritizing value and improved patient outcomes, over utilization and sickness.

A white paper from NPC and Discern Health analyzes the landscape of available patient-reported measures and patient-reported performance measures in oncology, and offers recommendations for filling gaps in measures and removing barriers to measure implementation in accountable care programs.

In his latest column in Specialty Pharmacy Times, NPC President and Chief Executive Officer Dan Leonard explains that rather than trying to score news headlines, what we need is a thoughtful, research-based approach to tackle the health care challenges ahead of us.